{"ORPHApacket":[{"ORPHApacketID":"279894","date":"2019-12-06 02:12:48","version":"1.3.1 \/ 4.1.7 [2019-11-24] (orientdb version)","copyright":"Orphanet (c) 2019","ORPHA":"279894","Name":[{"lang":"en","label":"Toxic maculopathy due to antimalarial drugs"}],"PURL":"http:\/\/www.orpha.net\/ORDO\/Orphanet_279894","DisorderType":[{"Name":[{"lang":"en","label":"Disease"}],"PURL":"http:\/\/www.orpha.net\/ORDO\/Orphanet_377788"}],"SubClassOfList":[{"Disorder":[{"Name":[{"lang":"en","label":"Rare retinal disorder"}],"ORPHA":"519315","PURL":"http:\/\/www.orpha.net\/ORDO\/Orphanet_519315"}]}],"TextSection":[{"Name":[{"lang":"en","label":"Definition"}],"Contents":"Toxic maculopathy due to antimalarial drugs is a rare, acquired eye disease, due to long-term exposure to chloroquinine (CQ) or hydrochloroquinine (HCQ), characterized by a slowly progressive, usually non-reversible, development of bilateral atrophic bull's-eye maculopathy (progressive loss of central vision acuity, reduced color vision and central scotoma), which in severe cases can spread over the entire fundus, leading to widespread retinal atrophy and visual loss."}],"AverageAgeOfOnsetList":[{"count":"1","AverageAgeOfOnset":[{"Name":[{"lang":"en","label":"All ages"}]}]}],"TypeOfInheritanceList":[{"count":"1","TypeOfInheritance":[{"Name":[{"lang":"en","label":"Not applicable"}]}]}]}]}